Manish A. Shah spends much of his time researching Internal medicine, Cancer, Gastroenterology, Oncology and Surgery. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Placebo. His Cancer research is multidisciplinary, incorporating elements of Disease, Cohort and Pathology.
His Gastroenterology research is multidisciplinary, relying on both Malignancy, Fluorouracil, Carcinoma, Docetaxel and Breast cancer. Manish A. Shah has researched Oncology in several fields, including Regimen and Stomach. His study explores the link between Surgery and topics such as Tolerability that cross with problems in Febrile neutropenia, Trastuzumab emtansine, Taxane, Pharmacokinetics and Biopsy.
Manish A. Shah focuses on Internal medicine, Cancer, Oncology, Chemotherapy and Gastroenterology. His biological study spans a wide range of topics, including Placebo and Surgery. His Cancer study combines topics from a wide range of disciplines, such as Cancer research and Malignancy, Disease, Clinical trial, Pathology.
His Oncology study incorporates themes from Pembrolizumab, Irinotecan, Colorectal cancer, Docetaxel and Bevacizumab. The Chemotherapy study combines topics in areas such as Randomized controlled trial and Trastuzumab. His Gastroenterology research integrates issues from Gastroesophageal Junction Adenocarcinoma, Carcinoma and Metastasis.
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Pembrolizumab and Chemotherapy. His studies in Internal medicine integrate themes in fields like Gastroenterology and Placebo. In his work, Intention-to-treat analysis, Performance status, Sudden death, Adverse effect and Progression-free survival is strongly intertwined with Clinical endpoint, which is a subfield of Gastroenterology.
The concepts of his Oncology study are interwoven with issues in Trastuzumab, MEDLINE, Phases of clinical research, Regimen and Biomarker. His study brings together the fields of Cancer research and Cancer. His Pembrolizumab study integrates concerns from other disciplines, such as PD-L1, Carcinoma, Gastroesophageal Junction Adenocarcinoma and Esophageal cancer.
His scientific interests lie mostly in Internal medicine, Oncology, Pembrolizumab, Cancer and Advanced esophageal cancer. His study in Gastroenterology extends to Internal medicine with its themes. Manish A. Shah interconnects Hematology and MEDLINE in the investigation of issues within Oncology.
His Pembrolizumab research focuses on Esophageal cancer and how it connects with Adverse effect, Esophagus and Carcinoma. His study in the fields of PD-L1 and Immunotherapy under the domain of Cancer overlaps with other disciplines such as 2019-20 coronavirus outbreak. His Advanced esophageal cancer research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
Marcy E. MacDonald;Christine M. Ambrose;Mabel P. Duyao;Richard H. Myers.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
M Shah;N Datson;L Srinidhi;VP Stanton.
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
Ki Young Chung;Jinru Shia;Nancy E. Kemeny;Manish Shah.
Journal of Clinical Oncology (2005)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha.
Journal of Clinical Oncology (2011)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro.
JAMA Oncology (2018)
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Gary K. Schwartz;Manish A. Shah.
Journal of Clinical Oncology (2005)
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor.
Journal of Clinical Oncology (2006)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu.
Journal of Clinical Oncology (2012)
Gastric cancer epidemiology and risk factors.
Douglas E. Guggenheim;Manish A. Shah.
Journal of Surgical Oncology (2013)
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Manish A. Shah;Gary K. Schwartz.
Clinical Cancer Research (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: